Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype
Open Access
- 5 January 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Breast Cancer
- Vol. 21 (4), e402-e414
- https://doi.org/10.1016/j.clbc.2020.12.013
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestationsBreast Cancer Research and Treatment, 2011
- Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II studyAnnals of Oncology, 2010
- Survival among women with triple receptor-negative breast cancer and brain metastasesAnnals of Oncology, 2009
- Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patientsBritish Journal of Cancer, 2009
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast CancerClinical Cancer Research, 2009
- Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancerCancer, 2008
- Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survivalJournal of Neuro-Oncology, 2008
- Survival in patients with brain metastases from breast cancerCancer, 2008
- Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II studyJournal of Neuro-Oncology, 2005
- Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinomaCancer, 2003